scholarly journals Polymorphisms in CLDN1 are associated with age and differentiation of triple-negative breast cancer patients

2019 ◽  
Vol 39 (4) ◽  
Author(s):  
Aimin Hu ◽  
Junyu Li ◽  
Shufang Ruan ◽  
Ying Fan ◽  
Yuqian Liao
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Clinicopathological Characteristics ◽  
Lymph Node Status ◽  
Nucleotide Polymorphisms ◽  
Breast Cancer Patients ◽  
Hazard Ratios ◽  
Novel Biomarkers ◽  
Grade 3

Abstract Purpose: Triple-negative breast cancer (TNBC) is a highly heterogeneous disease. It is very important to explore novel biomarkers to better clarify the characteristics of TNBC. It has been reported that polymorphisms in claudin 1 (CLDN1) are associated with risk of several cancers. But till now, there is no report about these polymorphisms and TNBC. Patients and methods: Between January 2004 and December 2013, 267 patients with stage I–III primary TNBC were included in our study. We investigated the association between polymorphisms in CLDN1 gene and clinicopathological characteristics or survival of these patients. We used Haploview 4.2 software to identify Tag single nucleotide polymorphisms (SNPs). MassARRAY MALDI-TOF System was used for genotyping. Results: We found that rs10513846 GA genotype was associated with older age [P=0.013, hazard ratios (HR) = 2.231, 95% confidence interval (CI): 1.186–4.195]. Rs10513846 AA genotype carriers were more likely to develop grade 3 tumors (P=0.005, HR = 2.889, 95% CI: 1.389–6.007). And rs9283658 genotypes were also related to grade, more patients with grade 3 tumors were rs9283658 CC genotype carriers (P=0.023, HR = 0.446, 95% CI: 0.222–0.894). There was no association between polymorphisms in CLDN1 and survival of TNBC patients. After multivariate analysis, tumor size (P=0.021, HR = 3.146, 95% CI: 1.185–8.354) and lymph node status (P<0.001, HR = 10.930, 95% CI: 3.276–36.470) were demonstrated to be independent prognostic factors. Conclusion: We first demonstrated that polymorphisms in CLDN1 gene were associated with age and differentiation of TNBC patients.

A retrospective single-center study investigating the clinical significance of grade in triple-negative breast cancer.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e13108-e13108
Author(s):  
Caroline M. Hamm
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Patients ◽  
Ongoing Research ◽  
Risk Of Death ◽  
Increased Risk ◽  
Grade 3 ◽  
Time To Relapse

e13108 Background: Triple negative breast cancer is defined as estrogen (ER), progesterone (PR), and human epidermal growth factor receptor (HER-2) proteins negative. The grade is the degree of similarity of tumor cells to normal cells under microscope and is an important biomarker of overall patient outcomes or prognosis with higher grades having a poor prognosis. As recent chemotherapy trials noted moderately undifferentiated grade 2 tumors showing higher rates of relapse, we hypothesize that grade can also be a predictive biomarker or determinant of response to specific treatment. Methods: We reviewed 305 patient charts of triple negative breast cancer patients from 2004-2017 at Windsor Regional Cancer Center analyzing the significance of grade with respect to oncological variables, survival-time, and time to relapse. Statistical analysis was performed using Fleming-Harrington, Pairwise Testing, and COX regression, where applicable. Results: Univariate analysis showed statistically significance difference in chemotherapy type (P = 0.008) and a marginal one in ER & hormone therapy status (P ~0.09) between the grades. The overall survival rates were 90.12%, 64.4%, and 77.2%, for grade 1, 2, 3 respectively. The overall difference in survival among the three groups was statistically significant, based on Fleming-Harrington test (P = 0.019). Comparing only between grade 2 and grade 3, we found that after five years, grade 2 patients had a 5.5-fold increased risk of death (HR = 5.5; 95% CI 1.2-25.6) and 2-folds higher risk of relapse (HR = 1.9; 95% CI 1.1-3.2). Grade 3 does significantly better than grade 2 in time to relapse with relapse rates of 70%, 55.6 %, and 75.6%, respectively for grades 1, 2, and 3 (P = 0.04). Conclusions: Tumor grade has a significant positive predictive value in determining relapse with grade 2 tumors demonstrating poorer disease-free survival as compared to grade 1 & 3, less time to relapse, and increased risk of death. This has implications in stratifying triple negative breast cancer patients by grade in future clinical trials while ongoing research yields new targets for chemotherapy.

scholarly journals Ethnicity-Related Survival Analysis of Patients with Triple-Negative Breast Cancer

10.29007/f7fq ◽  
2019 ◽  
Author(s):  
Mohammad Owrang Ojaboni ◽  
Yasmine Kanaan ◽  
Robert Dewitty Jr
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Prognostic Significance ◽  
Growth Factor Receptor ◽  
Population Based ◽  
Lymph Node Status ◽  
Breast Cancer Patients ◽  
The Poor ◽  
Clinical Difference

Breast cancer prognostication is a vital element for providing effective treatment for breast cancer patients. Different types of breast cancer can be identified based on the existence or lack of certain receptors (i.e., estrogen, progesterone, her2 receptors). Triple-negative breast cancer (TNBC) is characterized by a lack of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) expression. Existing studies suggest that TNBC patients tend to have worse prognosis compared to non-TNBC counterparts. The incidence of breast cancer and prognosis in women differ according to ethnicity. Given the poor prognosis of TNBC, cancer-related outcomes must be estimated accurately. Several factors responsible for the poor clinical outcomes observed in TNBC, including age, race/ethnicity, grade, tumor size, lymph node status among others, have been studied extensively. Available research data are not conclusive enough to make a convincing argument for or against a biological or clinical difference in TNBC patients based on these factors. This study was designed to investigate the effects of the ethnicity on breast cancer survivability among TNBC patients utilizing population-based Surveillance, Epidemiology, and End Results (SEER) data to confirm whether ethnicity factor has prognostic significance.

Sign in / Sign up

Export Citation Format

Share Document